--- title: "Ardelyx (ARDX) Valuation Check After Recent Share Price Weakness And Growth Expectations" type: "News" locale: "en" url: "https://longbridge.com/en/news/278501166.md" description: "Ardelyx (ARDX) is currently trading at $6.17, reflecting a 15.71% decline over the past month, despite a 1-year total shareholder return of 17.75%. The company shows strong revenue growth of 22.8% annually but is still operating at a net loss of $61.60 million. Analysts suggest the stock is undervalued with a Price-to-Sales ratio of 3.7x compared to industry averages. A DCF model estimates a fair value of $58.76 per share, indicating significant upside potential. However, risks remain regarding the adoption of its treatments, IBSRELA and XPHOZAH." datetime: "2026-03-10T06:29:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278501166.md) - [en](https://longbridge.com/en/news/278501166.md) - [zh-HK](https://longbridge.com/zh-HK/news/278501166.md) --- # Ardelyx (ARDX) Valuation Check After Recent Share Price Weakness And Growth Expectations Without a clear single event driving headlines today, Ardelyx (ARDX) still attracts attention as investors weigh recent share performance against its current market pricing and underlying business results. See our latest analysis for Ardelyx. At a share price of $6.17, Ardelyx has recently seen a 15.71% 1 month share price decline after a softer 7 day move. However, its 1 year total shareholder return of 17.75% and 3 year total shareholder return of 65.42% suggest longer term holders have still come out ahead. If this kind of mixed momentum has you thinking about other opportunities in healthcare, it could be a good moment to check out 32 healthcare AI stocks as a starting list of ideas. With Ardelyx posting double digit annual revenue growth alongside a net loss and trading at $6.17 versus an analyst target of $16.10, is the market underestimating its prospects or already pricing in future growth? ## Preferred Price-to-Sales of 3.7x: Is it justified? On the latest figures, Ardelyx trades on a P/S of 3.7x at a share price of $6.17, which screens as cheap compared to peers and the wider US Biotechs industry. The P/S ratio compares the company’s market value to its revenue, so it is often used for businesses that are still loss making but generating meaningful sales. For Ardelyx, this fits its profile of $407.32m in revenue alongside a net loss of $61.60m, where earnings based metrics are less useful. Relative to peers and the sector, Ardelyx’s 3.7x P/S sits well below both the peer average of 10.3x and the US Biotechs industry average of 12.3x, a sizeable gap for a company with forecast annual revenue growth of 22.8% and expectations that earnings will grow 52.04% per year and turn profitable within three years. Against the SWS estimated fair P/S of 7.1x, the current multiple also sits at a discount. This is framed as a level the market could move toward if those forecasts play out. Explore the SWS fair ratio for Ardelyx **Result: Price-to-Sales of 3.7x (UNDERVALUED)** ## DCF fair value points to a wide gap Our DCF model estimates a future cash flow value of $58.76 for Ardelyx, compared with the recent share price of $6.17, implying a very large discount in the current market price. The SWS DCF model projects Ardelyx’s future cash flows over time and then discounts them back to today using a required rate of return. It aims to capture the value of those expected future cash streams in a single present value figure. This approach can be helpful for a company that is still loss making today but where analysts are forecasting 22.8% annual revenue growth and a shift to profitability within the next three years. For a biotech business like Ardelyx, where current earnings do not yet reflect the potential of its commercialized treatments IBSRELA and XPHOZAH, a cash flow based lens can highlight how much of that expected growth and profitability is, or is not, reflected in the current share price. Look into how the SWS DCF model arrives at its fair value. **Result: DCF Fair value of $58.76 (UNDERVALUED)** However, you also need to weigh risks, including Ardelyx’s current net loss of $61.60m and the possibility that expectations for IBSRELA and XPHOZAH adoption prove too optimistic. Find out about the key risks to this Ardelyx narrative. ## Another angle on what the market is pricing in Our DCF model presents a different perspective, with an estimated value of $58.76 per share versus the current $6.17 price, which appears significantly undervalued. If both the P/S and DCF indicate potential upside, the key question is which set of assumptions you consider more reliable. Look into how the SWS DCF model arrives at its fair value. ARDX Discounted Cash Flow as at Mar 2026 Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ardelyx for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. ## Next Steps Given the mixed signals in this story, if you are considering whether the current price really matches the risks and rewards on the table, take a moment to review the full picture for yourself with 4 key rewards and 1 important warning sign. ## Looking for more investment ideas? If you are serious about building a stronger portfolio, do not stop with just one stock story. Use the screener to surface more potential opportunities. - Target income first by scanning for companies in 14 dividend fortresses that may offer higher yields with the backing of solid fundamentals. - Hunt for quality at a price that looks appealing by reviewing screener containing 23 high quality undiscovered gems that the broader market may not be paying close attention to yet. - Prioritise resilience by focusing on 63 resilient stocks with low risk scores that score well on financial strength and business stability. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [ARDX.US](https://longbridge.com/en/quote/ARDX.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) ## Related News & Research - [Fulcrum Therapeutics Q1 net loss widens on higher expenses](https://longbridge.com/en/news/284202157.md) - [AbbVie beats Q1 revenue, profit estimates on Skyrizi, Rinvoq demand; lifts profit outlook](https://longbridge.com/en/news/284564851.md) - [Illumina Q1 revenue beats on demand for NovaSeq X](https://longbridge.com/en/news/284828330.md) - [Biopharma firm Incyte's Q1 revenue, adjusted profit beat estimates](https://longbridge.com/en/news/284370688.md) - [Moderna (NASDAQ:MRNA) Announces Earnings Results](https://longbridge.com/en/news/284945405.md)